Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine, Ruxolitinib, and Secukinumab in COVID-19
NCT04403243Phase 2Completed
- Sponsor
- Lomonosov Moscow State University Medical Research and Educational Center
- Start
- May 2020
- Primary completion
- Jul 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of colchicine in coronavirus disease 2019 (COVID-19), sponsored by Lomonosov Moscow State University Medical Research and Educational Center. Started May 2020; status: completed.
02
Drugs
colchicine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04403243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403243.